Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology and hematology, today provided an update regarding anticipated milestones for the analysis of data and potential regulatory filing related to the pivotal, registrational BELIEF trial of belinostat, a novel histone deacetylase (HDAC) inhibitor. On September 21, 2012, Topotarget A/S, Spectrum’s collaboration partner for the joint development of belinostat, reported preliminary clinical results for the BELIEF trial, which is evaluating the efficacy and safety of belinostat for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL). Spectrum is continuing to collect and analyze the data from the trial, and database lock is expected to occur in November/December 2012, following which a definitive determination of the primary endpoint of overall response rate (ORR) will be calculated.
“We are very pleased with the ongoing data collection and its analysis from the BELIEF trial and look forward to a required meeting with the FDA once a definitive ORR has been determined," stated Rajesh C. Shrotriya, M.D., Chairman, President and Chief Executive Officer of Spectrum Pharmaceuticals, Inc. “Pending final data analysis and agreement with the FDA, we anticipate filing of an NDA application by mid-2013, and FDA decision is likely in 2014.”
About Peripheral T-Cell Lymphoma
According to the Lymphoma Research Foundation ( www.lymphoma.org), lymphoma is the most common blood cancer. The two main forms of lymphoma are Hodgkin's lymphoma and non-Hodgkin's lymphoma (NHL). Lymphoma occurs when lymphocytes, a type of white blood cell, grow abnormally where they typically reside in the lymph glands. The body has two main types of lymphocytes that can develop into lymphomas: B-lymphocytes (B-cells) and T-lymphocytes (T-cells). Peripheral T-cell lymphoma (PTCL) comprises a group of rare and aggressive NHLs that develop from mature T-cells. PTCL accounts for approximately 10 to 15% of all NHL cases in the United States, and projections for annual cancer incidences point to 15,500 new cases of PTCL in the U.S., Japan, and five of the largest EU countries.FOLOTYN® (pralatrexate injection), the first therapeutic approved for the treatment of PTCL, is marketed by Spectrum pursuant to the Company’s recent acquisition of Allos Therapeutics, Inc.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV